EGFR and colorectal cancer: Preclinical studies suggest that the lack of efficacy in BRAFV600E colorectal cancer is due to adaptive feedback reactivation of mitogen-activated protein kinase signalling, often mediated by epidermal growth factor receptor (EGFR) [4].